Tags

Type your tag names separated by a space and hit enter

Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens.
Bone Marrow Transplant. 2006 Dec; 38(11):739-43.BM

Abstract

To compare the outcome of hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) conditioned with two different regimens: (1) single dose of VP16 (60 mg/kg over 4 h) and total body irradiation (TBI; 1200 cGy, in six fractions) or (2) Cyclophosphamide 50 mg/kg over 1 h daily for 4 days followed by the same dose of TBI. One hundred and seven children with ALL received fully matched HSCT from 1990 to 2003 in the Hospital for Sick Children, Toronto. All received cyclosporin A and a short course of methotrexate for graft-versus-host disease (GVHD) prophylaxis. The VP16 group, there were 36 matched related donor transplants (MRD) and 26 matched unrelated donor transplants (MUD), and in the cyclophosphamide group there were 23 MRD and 22 MUD transplants. Neutrophil engraftment occurred at a median of 18 and 17 days for the VP16/TBI and the CY/TBI groups, respectively. The 3 year event-free survival and overall survival were 47 +/- 7 and 55 +/- 7% for those receiving VP16/TBI, and 51 +/- 8 and 53 +/- 8% for the CY/TBI group. There were no significant differences in the prevalence of acute or chronic GVHD and transplant-related mortality between the two groups. Both VP16/FTBI and CY/FTBI regimen are equally effective regimens.

Authors+Show Affiliations

Division of Hematology/Oncology/Bone Marrow Transplantation, The Hospital for Sick Children, University of Toronto, Ontario, Canada. adam.gassas@sickkids.caNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17013424

Citation

Gassas, A, et al. "Comparative Outcome of Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Following Cyclophosphamide and Total Body Irradiation or VP16 and Total Body Irradiation Conditioning Regimens." Bone Marrow Transplantation, vol. 38, no. 11, 2006, pp. 739-43.
Gassas A, Sung L, Saunders EF, et al. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplant. 2006;38(11):739-43.
Gassas, A., Sung, L., Saunders, E. F., & Doyle, J. J. (2006). Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. Bone Marrow Transplantation, 38(11), 739-43.
Gassas A, et al. Comparative Outcome of Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Following Cyclophosphamide and Total Body Irradiation or VP16 and Total Body Irradiation Conditioning Regimens. Bone Marrow Transplant. 2006;38(11):739-43. PubMed PMID: 17013424.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens. AU - Gassas,A, AU - Sung,L, AU - Saunders,E F, AU - Doyle,J J, Y1 - 2006/10/02/ PY - 2006/10/3/pubmed PY - 2007/1/19/medline PY - 2006/10/3/entrez SP - 739 EP - 43 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 38 IS - 11 N2 - To compare the outcome of hematopoietic stem cell transplantation (HSCT) in pediatric acute lymphoblastic leukemia (ALL) conditioned with two different regimens: (1) single dose of VP16 (60 mg/kg over 4 h) and total body irradiation (TBI; 1200 cGy, in six fractions) or (2) Cyclophosphamide 50 mg/kg over 1 h daily for 4 days followed by the same dose of TBI. One hundred and seven children with ALL received fully matched HSCT from 1990 to 2003 in the Hospital for Sick Children, Toronto. All received cyclosporin A and a short course of methotrexate for graft-versus-host disease (GVHD) prophylaxis. The VP16 group, there were 36 matched related donor transplants (MRD) and 26 matched unrelated donor transplants (MUD), and in the cyclophosphamide group there were 23 MRD and 22 MUD transplants. Neutrophil engraftment occurred at a median of 18 and 17 days for the VP16/TBI and the CY/TBI groups, respectively. The 3 year event-free survival and overall survival were 47 +/- 7 and 55 +/- 7% for those receiving VP16/TBI, and 51 +/- 8 and 53 +/- 8% for the CY/TBI group. There were no significant differences in the prevalence of acute or chronic GVHD and transplant-related mortality between the two groups. Both VP16/FTBI and CY/FTBI regimen are equally effective regimens. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/17013424/Comparative_outcome_of_hematopoietic_stem_cell_transplantation_for_pediatric_acute_lymphoblastic_leukemia_following_cyclophosphamide_and_total_body_irradiation_or_VP16_and_total_body_irradiation_conditioning_regimens_ L2 - https://doi.org/10.1038/sj.bmt.1705515 DB - PRIME DP - Unbound Medicine ER -